RT Journal Article
SR Electronic
T1 Network-based integrative analysis of lithium response in bipolar disorder using transcriptomic and GWAS data
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.01.10.21268493
DO 10.1101/2022.01.10.21268493
A1 Vipavee Niemsiri
A1 Sarah Brin Rosenthal
A1 Caroline M. Nievergelt
A1 Adam X. Maihofer
A1 Maria C. Marchetto
A1 Renata Santos
A1 Tatyana Shekhtman
A1 Ney Alliey-Rodriguez
A1 Amit Anand
A1 Yokesh Balaraman
A1 Wade H. Berrettini
A1 Holli Bertram
A1 Katherine E. Burdick
A1 Joseph R. Calabrese
A1 Cynthia V. Calkin
A1 Carla Conroy
A1 William H. Coryell
A1 Anna DeModena
A1 Scott Feeder
A1 Carrie Fisher
A1 Nicole Frazier
A1 Mark A. Frye
A1 Keming Gao
A1 Julie Garnham
A1 Elliot S. Gershon
A1 Fernando Goes
A1 Toyomi Goto
A1 Gloria J. Harrington
A1 Petter Jakobsen
A1 Masoud Kamali
A1 Marisa Kelly
A1 Susan G. Leckband
A1 Falk Lohoff
A1 Michael J. McCarthy
A1 Melvin G. McInnis
A1 David Craig
A1 Caitlin E. Millett
A1 Francis Mondimore
A1 Gunnar Morken
A1 John I. Nurnberger
A1 Claire O’ Donovan
A1 Ketil J. Øedegaard
A1 Kelly Ryan
A1 Martha Schinagle
A1 Paul D. Shilling
A1 Claire Slaney
A1 Emma K. Stapp
A1 Andrea Stautland
A1 Bruce Tarwater
A1 Peter P. Zandi
A1 Martin Alda
A1 Kathleen M. Fisch
A1 Fred H. Gage
A1 John R. Kelsoe
YR 2022
UL http://medrxiv.org/content/early/2022/01/14/2022.01.10.21268493.abstract
AB Lithium (Li) is one of the most effective drugs for treating bipolar disorder (BD), however, there is presently no way to predict response to guide treatment. The aim of this study is to identify functional genes and pathways that distinguish BD Li responders (LR) from BD Li non-responders (NR). An initial Pharmacogenomics of Bipolar Disorder study (PGBD) GWAS of lithium response did not provide any significant results. As a result, we then employed network-based integrative analysis of transcriptomic and genomic data. In transcriptomic study of iPSC-derived neurons, 41 significantly differentially expressed (DE) genes were identified in LR vs NR regardless of lithium exposure. In the PGBD, post-GWAS gene prioritization using the GWA- boosting (GWAB) approach identified 1119 candidate genes. Following DE-derived network propagation, there was a highly significant overlap of genes between the top 500- and top 2000-proximal gene networks and the GWAB gene list (Phypergeometric=1.28E- 09 and 4.10E-18, respectively). Functional enrichment analyses of the top 500 proximal network genes identified focal adhesion and the extracellular matrix (ECM) as the most significant functions. Our findings suggest that the difference between LR and NR was a much greater effect than that of lithium. The direct impact of dysregulation of focal adhesion on axon guidance and neuronal circuits could underpin mechanisms of response to lithium, as well as underlying BD. It also highlights the power of integrative multi-omics analysis of transcriptomic and genomic profiling to gain molecular insights into lithium response in BD.Competing Interest StatementJIN is an investigator for Janssen Pharmaceuticals, Inc. (US Headquarters, Raritan, NJ). No other author declares a conflict of interest.Funding StatementThe study was primarily supported by a grant to JRK from the NIMH (U01 MH92758) as part of the Pharmacogenomics Research Network (PGRN) and a grant from the Department of Veterans Affairs. KMF is supported by a grant from the National Center for Advancing Translational Sciences, part of the NIH, as part of support for the UCSD CTSA (UL1TR001442). FHG and MCM are supported by U19MH106434, part of the National Cooperative Reprogrammed Cell Research Groups (NCRCRG) to Study Mental Illness. FHG is also supported by grants from AHA-Allen Initiative in Brain Health and Cognitive Impairment Award made jointly through the American Heart Association and The Paul G. Allen Frontiers Group (19PABH134610000), The JPB Foundation, Bob and Mary Jane Engman, Annette C. Merle-Smith, R01 MH095741, and Lynn and Edward Streim. The Halifax group (MA, CVC, JG, CO, and CS) is supported by grants from Canadian Institutes of Health Research (#166098), ERA PerMed project PLOT-BD, Research Nova Scotia, Genome Atlantic, Nova Scotia Health Authority and Dalhousie Medical Research Foundation (Lindsay Family Fund).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Human Research Protection Program of UCSD gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors.